BACKGROUND
The accumulation of visceral adipose tissue (VAT) and ectopic liver fat (ELF) generally parallel each other, but a proportion of individuals have discordant fat deposition. The cardiometabolic profile of individuals with a discordant phenotype is unknown.
METHODS
Amongst participants in the multiethnic Dallas Heart Study cohort, the authors examined the cross-sectional associations of VAT–ELF phenotypes with circulating biomarkers of insulin resistance, dyslipidaemia, inflammation, and subclinical atherosclerosis. VAT and ELF were assessed by MRI and magnetic resonance spectroscopy, respectively. Participants were stratified into phenotype groups: low VAT–low ELF, low VAT–high ELF, high VAT–low ELF, and high VAT–high ELF, defined by median sex and race-specific values for VAT and ELF. Associations between phenotype groups and biomarkers were adjusted for age, sex, race, menopausal status (females only), and BMI (referent low VAT–low ELF).
RESULTS
In multivariable models, high VAT–low ELF was significantly associated with insulin resistance (homeostatic model assessment of insulin resistance [HOMA-IR]); lower adiponectin concentration; higher low-density lipoprotein (LDL) cholesterol and more small, dense LDL particles; lower high-density lipoprotein (HDL) cholesterol and fewer large HDL particles; higher high-sensitivity C-reactive protein and myeloperoxidase levels; increased aortic wall thickness; and higher odds of hypertension, diabetes, and metabolic syndrome (Table 1). Low VAT–high ELF showed similar patterns, except that there was no independent association with aortic atherosclerosis, myeloperoxidase, or LDL cholesterol (Table 1).
CONCLUSION
High VAT–low ELF is associated with an adverse atherosclerotic, dyslipidaemic, dysmetabolic, and inflammatory phenotype, whereas the profile of low VAT–high ELF is more variable. These findings suggest phenotypic heterogeneity of abdominal and liver fat distribution with markers of cardiometabolic risk, and provide insight into the biological roles of VAT and liver fat in cardiometabolic disease.